{"id":"infliximab-methylprednisolone-methotrexate","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Infection (including serious/opportunistic)"},{"rate":"5-10","effect":"Infusion reactions"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":null,"effect":"Immunosuppression-related malignancy risk"},{"rate":"1-3","effect":"Tuberculosis reactivation"},{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"1-5","effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL1201581","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a TNF-α inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha, a key inflammatory cytokine. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase and reduces T-cell proliferation. Methylprednisolone is a corticosteroid that broadly suppresses immune activation. Together, these agents provide multi-modal immunosuppression for severe inflammatory conditions.","oneSentence":"This combination suppresses TNF-α signaling and T-cell proliferation to reduce inflammatory immune responses in autoimmune diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:50.502Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT01308255","phase":"PHASE4","title":"Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00908089","phase":"PHASE4","title":"TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01724268","phase":"PHASE3","title":"Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2012-05","conditions":"RHEUMATOID ARTHRITIS","enrollment":80},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00554710","phase":"PHASE4","title":"Top Down Versus Step Up Strategies in Crohn's Disease","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2001-05","conditions":"Crohn's Disease","enrollment":129},{"nctId":"NCT00396747","phase":"PHASE4","title":"A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study","status":"COMPLETED","sponsor":"Université Catholique de Louvain","startDate":"2003-06","conditions":"Rheumatoid Arthritis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":54,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Infliximab, methylprednisolone, methotrexate","genericName":"Infliximab, methylprednisolone, methotrexate","companyName":"Université Catholique de Louvain","companyId":"universit-catholique-de-louvain","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses TNF-α signaling and T-cell proliferation to reduce inflammatory immune responses in autoimmune diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}